Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06899217 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.

A Phase 2 study of Idiopathic Gastroparesis, sponsored by CinDome Pharma.

Active
Registry status
Phase 2
Development phase
416
Enrollment target
20
Study locations

NCT06899217 is a Phase 2 study of Idiopathic Gastroparesis that is active but no longer recruiting, run by CinDome Pharma. The registered enrollment target is 416 participants, above the 126-participant average among 4 other Idiopathic Gastroparesis trials with a reported enrollment target (230% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06899217, a Phase 2 study of Idiopathic Gastroparesis, is active but no longer recruiting, sponsored by CinDome Pharma.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
416 participants
Enrollment target
20
Study locations

Study Summary

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopathic gastroparesis severity in adult subjects. The main questions it aims to answer are: * To evaluate the efficacy of CIN-102 on symptoms of gastroparesis when given to patients with idiopathic gastroparesis compared to a placebo * To evaluate the safety of CIN-102 when given to patients with idiopathic gastroparesis compared to a placebo Participants will go through the following schedule: * Pre-screening (1 visit) * Screening \& Lead-In (1-2 visits) * Will complete a Gastric Emptying Breath Test (GEBT) * Will complete daily diary and other Patient Reported Outcomes (PROs) as described in the protocol to assess eligibility for continued study participation. * Lead-In Period (1 visit) * 12-week treatment period (7 visits) * Study drug taken twice daily by mouth * Will complete daily diaries and other PROs as described in protocol * 1 week follow-up (1 visit) Researchers will compare the effects of the following treatments: * 15 mg CIN-102, taken orally BID for 12 weeks * 10 mg CIN-102, taken orally BID for 12 weeks * Placebo for CIN-102, taken orally BID for 12 weeks

Conditions Studied

Idiopathic Gastroparesis

Interventions

  • DRUG Placebo
  • DRUG CIN-102 Dose 15mg
  • DRUG CIN-102 Dose 10mg

Study Locations (20)

California

  • Hope Clinical Research LLC - Canoga Park
  • Erick H. Alayo Medical Corporation - Chula Vista
  • Flourish Research - Los Angeles (Covina) - Covina
  • Gastro Care Institute - Lancaster
  • Downtown L.A. Research Center, Inc. - Los Angeles
  • Acclaim Clinical Research - San Diego
  • Focus Clinical Research - West Hills - West Hills

Alabama

  • Gastro Health - Birmingham - Birmingham
  • G & L Research, LLC - Foley
  • The Center for Clinical Trials - Saraland

Colorado

  • University of Colorado Anschutz - Aurora
  • Rocky Mountain Gastroenterology (RMG) - Lakewood
  • Paradigm Research - Wheatridge - Wheat Ridge

Florida

  • American Family Research Group - Cape Coral
  • USA and International Research Inc. - Doral
  • Unique Clinical Trials - Doral

Arkansas

  • Applied Research Center of Arkansas, Inc - Little Rock
  • Preferred Research Partners, Inc. - Little Rock

Arizona

  • Del Sol Research Management, LLC - Tucson

Connecticut

  • Connecticut Clinical Research Institute, LLC - Bristol

Trial Details

FieldValue
Enrollment Target 416 participants
Start Date 2025-01-29
Est. Completion 2026-05-01
Phase Phase 2

Sponsor

CinDome Pharma

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06899217

The ClinicalTrials.gov registry entry for NCT06899217 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 416 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 126-participant average among 4 other Idiopathic Gastroparesis trials with a reported enrollment target (230% higher). The listed sponsor is CinDome Pharma, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Idiopathic Gastroparesis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT06899217 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Alabama, Colorado.

Frequently Asked Questions

What is clinical trial NCT06899217 about?

NCT06899217 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.". The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopathic gastroparesis severity in adult subjects. The main questions it aims to answer are: * To evaluate the efficacy of CIN-102 on symptoms of gastrop...

What is the current status of trial NCT06899217?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 416 participants. The study started on 2025-01-29. Estimated completion is 2026-05-01.

What conditions does trial NCT06899217 study?

This clinical trial studies the following conditions: Idiopathic Gastroparesis.

What interventions are being tested in trial NCT06899217?

The interventions under investigation include: Placebo (DRUG), CIN-102 Dose 15mg (DRUG), CIN-102 Dose 10mg (DRUG).

Who is sponsoring clinical trial NCT06899217?

This trial is sponsored by CinDome Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06899217 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Idiopathic Gastroparesis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Idiopathic Gastroparesis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.